Alphabet’s AI-driven drug discovery company, Isomorphic Labs, has successfully raised $600 million in its first-ever funding round. The investment, led by Thrive Capital and Google Ventures, aims to accelerate breakthroughs in AI-assisted pharmaceutical research.
Isomorphic Labs, headquartered in London, has been working on developing advanced AI models to speed up drug discovery and revolutionize disease treatment. The company is best known for its AlphaFold technology, an AI system capable of accurately predicting protein structures, significantly reducing the time and cost required for medical research.
With this fresh funding, Isomorphic Labs plans to expand its AI capabilities, enhance its drug design engine, and strengthen partnerships with pharmaceutical giants like Eli Lilly and Novartis. The goal is to push the boundaries of AI in medicine, potentially leading to faster and more efficient drug development.
The company’s vision is bold: to use artificial intelligence to solve complex diseases and transform the way new medicines are created. This investment marks a major step forward in that mission, positioning Isomorphic Labs as a key player in the future of healthcare innovation.
